Beacon Investment Advisors LLC Acquires Shares of 165,556 Ocular Therapeutix, Inc. $OCUL

Beacon Investment Advisors LLC bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 165,556 shares of the biopharmaceutical company’s stock, valued at approximately $2,010,000. Beacon Investment Advisors LLC owned 0.08% of Ocular Therapeutix as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in OCUL. Steward Partners Investment Advisory LLC grew its holdings in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,242 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Ocular Therapeutix by 1.8% in the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 1,314 shares during the period. Trust Co. of Vermont increased its holdings in Ocular Therapeutix by 24.3% during the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,750 shares during the period. Rafferty Asset Management LLC grew its position in shares of Ocular Therapeutix by 21.2% during the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 2,343 shares in the last quarter. Finally, Creative Planning raised its holdings in shares of Ocular Therapeutix by 14.6% in the third quarter. Creative Planning now owns 24,535 shares of the biopharmaceutical company’s stock valued at $287,000 after acquiring an additional 3,125 shares in the last quarter. 59.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OCUL. William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Wall Street Zen downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Price Performance

NASDAQ OCUL opened at $8.94 on Wednesday. The firm’s fifty day simple moving average is $8.92 and its two-hundred day simple moving average is $9.95. The firm has a market capitalization of $1.96 billion, a P/E ratio of -6.12 and a beta of 0.90. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. Ocular Therapeutix, Inc. has a 12-month low of $6.23 and a 12-month high of $16.44.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider directly owned 2,597,170 shares of the company’s stock, valued at $21,296,794. This represents a 0.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 28,999 shares of company stock worth $237,792. Corporate insiders own 3.10% of the company’s stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.